首页>投融资
礼邦医药
C轮
礼邦医药是一家处于临床阶段的生物制药公司，具有强大的新药研发和临床开发能力。公司主要致力于肾脏病以及其他相关慢性疾病的创新药物发现和开发，为肾脏病及相关慢性疾病患者提供更佳的临床解决方案。礼邦医药已经建立起了丰富且均衡的肾脏病新药产品管线，包括针对慢性肾病（CKD）/透析并发症、IgA 肾病、糖尿病肾病和和常染色体显性多囊肾病等产品。
基本信息
-
公司全称上海礼邦医药科技有限公司
-
类型肾脏及慢性疾病治疗产品研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15~50人
-
地址中国（上海）自由贸易试验区芳春路400号1幢3层
-
联系电话021-60836201
-
邮箱yun.wang@alebund.com
-
成立时间2018-04-22
投融资
-
2023-04-12PreC轮2亿人民币泉创资本三正健康投资扬州龙川控股礼来亚洲基金Verition Fund Management扬州国金投资Octagon Capital鼎信资本
-
2023-04-12债权融资8亿人民币未透露
-
2023-04-12C轮2亿人民币礼来亚洲基金Verition Fund Management泉创资本三正健康投资鼎信资本扬州国金投资扬州龙川控股八方资本
-
2023-04-12债权融资8亿人民币未透露
-
2021-09-13B+轮5450万美元Quan Capital三正健康投资Octagon Capital八方资本礼来亚洲基金元生创投Verition Fund Management晨兴创投本草资本华图资本夏尔巴投资正心谷创新资本
-
2021-09-13B+轮5450万美元夏尔巴投资礼来亚洲基金泉创资本正心谷资本晨兴创投本草资本Verition Fund ManagementHT 资本元生创投八方资本三正健康投资
-
2021-05-10B轮6000万美元Quan Capital礼来亚洲基金五源资本本草资本夏尔巴投资幂方健康基金
-
2021-05-10B轮6000万美元礼来亚洲基金泉创资本五源资本本草资本幂方健康基金夏尔巴投资
-
2020-12-25A轮未透露华盖资本幂方资本礼来亚洲基金
-
2020-12-25A轮数千万人民币华盖资本幂方健康基金礼来亚洲基金
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息